hengrui glp 1 Investors put $400M into biotech licensing obesity drugs from China Jiangsu Hengrui Pharmaceuticals Out-Licenses GLP-1

Greenfield is transparent about using them under physician oversight

[248] The Neue Zrcher Zeitung wrote that "polemics alternate with chapters that pedantically seek to substantiate Kennedy's accusations with numerous quotations and studies"

BJPsych Adv

Denials are often due to a lack of medical necessity for weight loss alone, missing step therapy (trying cheaper drugs first), or incomplete prior authorization paperwork

Infections from the clinic or hospital setting make up a large portion of reported adverse events (or reactions), with surgical errors or mistakes while administering medication also contributing heavily to the number reported

cruzi are antitumor proteins